Efficacy of cabozantinib therapy for brain metastases from renal cell carcinoma

被引:4
作者
Nakagawa, Takashi [1 ]
Kijima, Toshiki [1 ]
Imasato, Naoki [1 ]
Nagoshi, Akihiko [1 ]
Nakamura, Gaku [1 ]
Uematsu, Toshitaka [1 ]
Suzuki, Issei [1 ]
Nishihara, Daisaku [1 ]
Kamai, Takao [1 ]
机构
[1] Dokkyo Med Univ, Dept Urol, 880 Kitakobayashi, Shimotsuga, Tochigi 3210293, Japan
关键词
brain metastases; cabozantinib; clear cell renal cell carcinoma; immunotherapy; radiotherapy; OPEN-LABEL; SUNITINIB; NIVOLUMAB; CANCER;
D O I
10.1002/iju5.12459
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: We report two cases of renal cell carcinoma with brain metastases that showed remarkable responses to cabozantinib. Case presentation: (Case 1) A 70-year-old man with cT3aN0M0 clear cell renal cell carcinoma underwent radical nephrectomy and developed multiple brain metastases 2months postoperatively. The brain lesions regressed after stereotactic radiotherapy followed by ipilimumab plus nivolumab therapy, but a new brain metastasis that caused hemiplegia developed after 6months and showed no response to stereotactic radiotherapy. However, complete remission was achieved, and hemiplegia ceased within 2weeks of cabozantinib therapy. (Case 2) A 63-year-old man with cT3aN0M1 clear cell renal cell carcinoma and brain metastases underwent upfront cytoreductive nephrectomy. The brain lesions progressed rapidly 1month postoperatively. The lesions disappeared 2 weeks after cabozantinib plus nivolumab therapy. Conclusion: Cabozantinib, alone or in combination with immune checkpoint inhibitors, may be a viable option for clear cell renal cell carcinoma with brain metastases.
引用
收藏
页码:293 / 296
页数:4
相关论文
共 20 条
[1]   A Phase II Trial of Sunitinib in Patients With Renal Cell Cancer and Untreated Brain Metastases [J].
Chevreau, Christine ;
Ravaud, Alain ;
Escudier, Bernard ;
Amela, Eric ;
Delva, Remy ;
Rolland, Frederic ;
Tosi, Diego ;
Oudard, Stephane ;
Blanc, Ellen ;
Ferlay, Celine ;
Negrier, Sylvie .
CLINICAL GENITOURINARY CANCER, 2014, 12 (01) :50-54
[2]   Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J].
Choueiri, T. K. ;
Powles, T. ;
Burotto, M. ;
Escudier, B. ;
Bourlon, M. T. ;
Zurawski, B. ;
Juarez, V. M. Oyervides ;
Hsieh, J. J. ;
Basso, U. ;
Shah, A. Y. ;
Suarez, C. ;
Hamzaj, A. ;
Goh, J. C. ;
Barrios, C. ;
Richardet, M. ;
Porta, C. ;
Kowalyszyn, R. ;
Feregrino, J. P. ;
Zolnierek, J. ;
Pook, D. ;
Kessler, E. R. ;
Tomita, Y. ;
Mizuno, R. ;
Bedke, J. ;
Zhang, J. ;
Maurer, M. A. ;
Simsek, B. ;
Ejzykowicz, F. ;
Schwab, G. M. ;
Apolo, A. B. ;
Motzer, R. J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09) :829-841
[3]   Systemic Therapy for Metastatic Renal-Cell Carcinoma [J].
Choueiri, Toni K. ;
Motzer, Robert J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (04) :354-366
[4]   Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial [J].
Choueiri, Toni K. ;
Escudier, Bernard ;
Powles, Thomas ;
Tannir, Nizar M. ;
Mainwaring, Paul N. ;
Rini, Brian I. ;
Hammers, Hans J. ;
Donskov, Frede ;
Roth, Bruce J. ;
Peltola, Katriina ;
Lee, Jae Lyun ;
Heng, Daniel Y. C. ;
Schmidinger, Manuela ;
Agarwal, Neeraj ;
Sternberg, Cora N. ;
McDermott, David F. ;
Aftab, Dana T. ;
Hessel, Colin ;
Old, Christian Scheff ;
Schwab, Gisela ;
Hutson, Thomas E. ;
Pal, Sumanta ;
Motzer, Robert J. .
LANCET ONCOLOGY, 2016, 17 (07) :917-927
[5]   Exceptional Response to Cabozantinib of Rapidly Evolving Brain Metastases of Renal Cell Carcinoma: A Case Report and Review of the Literature [J].
Ciccarese, Chiara ;
Iacovelli, Roberto ;
Mosillo, Claudia ;
Tortora, Giainpaolo .
CLINICAL GENITOURINARY CANCER, 2018, 16 (05) :E1069-E1071
[6]   Brain and pancreatic metastases: A clinico-pathological comparison of various facets of tumor heterogeneity in renal cell carcinoma - The BRAVE project [J].
Derosa, L. ;
Le Teuff, G. ;
Chanez, B. ;
Guida, A. ;
Ruatta, F. ;
Gravis, G. ;
Albiges, L. ;
Escudier, B. .
ANNALS OF ONCOLOGY, 2016, 27
[7]   Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC) and brain metastases: Preliminary results from the GETUG-AFU 26 (Nivoren) study. [J].
Escudier, Bernard J. ;
Chabaud, Sylvie ;
Borchiellini, Delphine ;
Gravis, Gwenaelle ;
Chevreau, Christine ;
Brachet, Pierre Emmanuel ;
Geoffrois, Lionnel ;
Laguerre, Brigitte ;
Mahammedi, Hakim ;
Negrier, Sylvie ;
Rolland, Frederic ;
Goupil, Marine Gross ;
Habibian, Muriel ;
Albiges, Laurence .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[8]   Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study [J].
Flippot, Ronan ;
Dalban, Cecile ;
Laguerre, Brigitte ;
Borchiellini, Delphine ;
Gravis, Gwenaelle ;
Negrier, Sylvie ;
Chevreau, Christine ;
Joly, Florence ;
Geoffrois, Lionnel ;
Ladoire, Sylvain ;
Mahammedi, Hakim ;
Rolland, Frederic ;
Gross-Goupil, Marine ;
Deluche, Elise ;
Priou, Frank ;
Laramas, Mathieu ;
Barthelemy, Philippe ;
Narciso, Berengere ;
Houede, Nadine ;
Culine, Stephane ;
Oudard, Stephane ;
Chenot, Marina ;
Tantot, Florence ;
Chabaud, Sylvie ;
Escudier, Bernard ;
Albiges, Laurence .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (23) :2008-+
[9]   Sunitinib in Metastatic Renal Cell Carcinoma Patients With Brain Metastases [J].
Gore, Martin E. ;
Hariharan, Subramanian ;
Porta, Camillo ;
Bracarda, Sergio ;
Hawkins, Robert ;
Bjarnason, Georg A. ;
Oudard, Stephane ;
Lee, Se-Hoon ;
Carteni, Giacomo ;
Nieto, Alejandra ;
Yuan, Jinyu ;
Szczylik, Cezary .
CANCER, 2011, 117 (03) :501-509
[10]   Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy [J].
Grassi, Paolo ;
Verzoni, Elena ;
Ratta, Raffaele ;
Mennitto, Alessia ;
de Braud, Filippo ;
Procopio, Giuseppe .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 :2167-2172